Multiple System Atrophy Market Outlook:
Multiple System Atrophy Market size was USD 150.1 million in 2025 and is anticipated to reach USD 230.8 million by the end of 2035, increasing at a CAGR of 4.9% during the forecast period, i.e., 2026-2035. In 2026, the industry size of multiple system atrophy is assessed at USD 157.4 million.
The rise in the international patient pool is the ultimate growth driver for the market. According to an article published by NLM in December 2023, the crude prevalence of MSA was 7.2 per 100,000, while there has been an increase in the U.S. to 41,122 people, from 12.4 per 100,000 population. Besides, for people with more than 2 MSA claims, the age-related and crude incidence have been 5.7 and 3.1 per 100,000 persons. On the other hand, the cumulative prevalence of MSA for patients over 30 years or older is 9.8 per 100,000 persons, which is deliberately uplifting the market’s demand globally.
Moreover, the aspect of the supply chain for MSA-based therapeutics comprising an inadequate number of active pharmaceutical ingredient (API) manufacturers, particularly in North America, is yet another factor for the multiple system atrophy market internationally. For instance, as per the April 2025 NLM article, API manufacturing for the market in Europe is effectively located in Asia, accounting for 56% of the supply, which is followed by 24% from West Europe and 12% from North America, and 8% from other nations. Besides, the existence of generic drugs, including fludrocortisone and levodopa, readily dominates the treatment procedure.
